CN1582166A - 在联合疗法中应用的玻璃粘连蛋白受体拮抗药物 - Google Patents

在联合疗法中应用的玻璃粘连蛋白受体拮抗药物 Download PDF

Info

Publication number
CN1582166A
CN1582166A CNA018144306A CN01814430A CN1582166A CN 1582166 A CN1582166 A CN 1582166A CN A018144306 A CNA018144306 A CN A018144306A CN 01814430 A CN01814430 A CN 01814430A CN 1582166 A CN1582166 A CN 1582166A
Authority
CN
China
Prior art keywords
alkyl
substituted
aryl
methyl
alkoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA018144306A
Other languages
English (en)
Chinese (zh)
Inventor
T·D·哈里斯
J·A·巴雷特
A·P·小卡彭特
M·拉乔帕耶
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Meyers Pharmaceutical Co
Bristol Myers Squibb Pharma Co
Original Assignee
Meyers Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Meyers Pharmaceutical Co filed Critical Meyers Pharmaceutical Co
Publication of CN1582166A publication Critical patent/CN1582166A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0038—Radiosensitizing, i.e. administration of pharmaceutical agents that enhance the effect of radiotherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0482—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group chelates from cyclic ligands, e.g. DOTA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
CNA018144306A 2000-06-21 2001-06-21 在联合疗法中应用的玻璃粘连蛋白受体拮抗药物 Pending CN1582166A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US21321000P 2000-06-21 2000-06-21
US60/213,210 2000-06-21

Publications (1)

Publication Number Publication Date
CN1582166A true CN1582166A (zh) 2005-02-16

Family

ID=22794168

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA018144306A Pending CN1582166A (zh) 2000-06-21 2001-06-21 在联合疗法中应用的玻璃粘连蛋白受体拮抗药物

Country Status (12)

Country Link
EP (1) EP1307226B1 (xx)
JP (1) JP2004521066A (xx)
CN (1) CN1582166A (xx)
AT (1) ATE414541T1 (xx)
AU (2) AU7296501A (xx)
BR (1) BR0111880A (xx)
CA (1) CA2412854C (xx)
DE (1) DE60136632D1 (xx)
IL (1) IL152941A0 (xx)
MX (1) MXPA02012750A (xx)
NZ (1) NZ522925A (xx)
WO (1) WO2001097848A2 (xx)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110898235A (zh) * 2018-09-14 2020-03-24 聚天生医股份有限公司 雌激素受体与大麻受体之间的相互交谈用组合物及其合成方法、套组、成像方法及应用

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6569402B1 (en) 1998-12-18 2003-05-27 Bristol-Myers Squibb Pharma Company Vitronectin receptor antagonist pharmaceuticals
WO2001085212A2 (en) * 2000-05-08 2001-11-15 The University Of British Columbia Drug delivery systems for photodynamic therapy
AU2001271435A1 (en) * 2000-06-21 2002-01-02 Bristol-Myers Squibb Pharma Company Vitronectin receptor antagonist pharmaceuticals
CN101249269A (zh) 2002-01-24 2008-08-27 巴内斯－朱威胥医院 整联蛋白靶向的影像剂
EP1475105A1 (en) * 2003-05-09 2004-11-10 Schering AG Bone localising radiopharmaceutical and tubulin-interacting compound combinatorial radiotherapy
US20060217292A1 (en) * 2003-05-12 2006-09-28 Harris Thomas D Vitronectin receptor antagonist compounds and their use in the preparation of diopharmaceuticals
EP3101012A1 (en) 2015-06-04 2016-12-07 Bayer Pharma Aktiengesellschaft New gadolinium chelate compounds for use in magnetic resonance imaging
KR102464647B1 (ko) 2016-11-28 2022-11-08 바이엘 파마 악티엔게젤샤프트 자기 공명 영상화에 사용하기 위한 높은 이완도 가돌리늄 킬레이트 화합물
BR112021007707A2 (pt) 2018-11-23 2021-07-27 Bayer Aktiengesellschaft formulação de meios de contraste e processo de preparação da mesma

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69736812T2 (de) * 1996-11-27 2007-08-09 Bristol-Myers Squibb Pharma Co. Neue integrin rezeptor antagonisten
US6120995A (en) * 1997-08-07 2000-09-19 Thomas Jefferson University Compositions that specifically bind to colorectal cancer cells and methods of using the same
US6093382A (en) * 1998-05-16 2000-07-25 Bracco Research Usa Inc. Metal complexes derivatized with folate for use in diagnostic and therapeutic applications
US6511648B2 (en) * 1998-12-18 2003-01-28 Bristol-Myers Squibb Pharma Company Vitronectin receptor antagonist pharmaceuticals
JP2005538030A (ja) * 2000-06-21 2005-12-15 デュポン ファーマシューティカルズ カンパニー 組み合わせ療法での使用のための血管新生障害の画像診断用医薬
AU2001271435A1 (en) * 2000-06-21 2002-01-02 Bristol-Myers Squibb Pharma Company Vitronectin receptor antagonist pharmaceuticals
AU2001270025B2 (en) * 2000-06-21 2005-08-18 Bristol-Myers Squibb Pharma Company Vitronectin receptor antagonist pharmaceuticals for use in combination therapy
AU2002218751A1 (en) * 2000-07-06 2002-01-21 Bristol-Myers Squibb Pharma Company Stable radiopharmaceutical compositions

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110898235A (zh) * 2018-09-14 2020-03-24 聚天生医股份有限公司 雌激素受体与大麻受体之间的相互交谈用组合物及其合成方法、套组、成像方法及应用
CN110898235B (zh) * 2018-09-14 2023-04-07 聚天生医股份有限公司 雌激素受体与大麻受体之间的相互交谈用组合物及其合成方法、套组、成像方法及应用

Also Published As

Publication number Publication date
DE60136632D1 (de) 2009-01-02
WO2001097848A2 (en) 2001-12-27
AU2001272965B2 (en) 2005-11-17
CA2412854C (en) 2010-08-17
AU2001272965C1 (en) 2006-06-29
ATE414541T1 (de) 2008-12-15
AU7296501A (en) 2002-01-02
WO2001097848A3 (en) 2003-03-13
MXPA02012750A (es) 2004-07-30
EP1307226A2 (en) 2003-05-07
EP1307226B1 (en) 2008-11-19
CA2412854A1 (en) 2001-12-27
IL152941A0 (en) 2003-06-24
BR0111880A (pt) 2006-04-25
NZ522925A (en) 2006-08-31
JP2004521066A (ja) 2004-07-15

Similar Documents

Publication Publication Date Title
CN1356913A (zh) 玻连蛋白受体拮抗剂药物
US6322770B1 (en) Indazole vitronectin receptor antagonist pharmaceuticals
AU2001270025A1 (en) Vitronectin receptor antagonist pharmaceuticals for use in combination therapy
WO2001098294A2 (en) Vitronectin receptor antagonist pharmaceuticals for use in combination therapy
US6524553B2 (en) Quinolone vitronectin receptor antagonist pharmaceuticals
US6558649B1 (en) Vitronectin receptor antagonist pharmaceuticals
US6838074B2 (en) Simultaneous imaging of cardiac perfusion and a vitronectin receptor targeted imaging agent
WO2001097861A2 (en) Vitronectin receptor antagonist pharmaceuticals
CN1298390C (zh) 心脏灌注和玻连蛋白受体靶向成像剂的同时成像
CN1582166A (zh) 在联合疗法中应用的玻璃粘连蛋白受体拮抗药物
US6548663B1 (en) Benzodiazepine vitronectin receptor antagonist pharmaceuticals
US6511649B1 (en) Vitronectin receptor antagonist pharmaceuticals
US7090828B2 (en) Vitronectin receptor antagonist pharmaceuticals
AU2001272965A1 (en) Vitronectin receptor antagonist pharmaceuticals
US7332149B1 (en) Vitronectin receptor antagonist pharmaceuticals

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication